Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III
Executive Summary
The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.